Investor Relations - Curis

Month Year

Investor Alerts

Nov 5, 2015

Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting

LEXINGTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Nov 2, 2015

Curis to Release Third Quarter 2015 Financial Results and Hold Conference Call on November 9, 2015

LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Nov 2, 2015

Curis Announces Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference

LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Oct 19, 2015

Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors

Company exercises options under Aurigene collaboration to license orally available small molecules for immuno-oncology and precision oncology

LEXINGTON, Mass., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Oct 14, 2015

Curis to Present at the BIO Investor Forum

LEXINGTON, Mass., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa